Business Context and Reporting Period
Company: Bruker Corporation (BRKR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Bruker develops, manufactures, and distributes high-performance scientific instruments and analytical/diagnostic solutions for life and materials science. The company operates through four reportable segments: BSI BioSpin (magnetic resonance, preclinical imaging), BSI CALID (mass spectrometry, molecular diagnostics, CBRNE detection), BSI NANO (X-ray, microscopy, spatial biology), and BEST (superconducting materials and energy technologies).
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) | Change |
|---|---|---|---|
| Total Revenue | $3,436.5 | $3,366.4 | +2.1% |
| Gross Profit | $1,577.7 | $1,649.5 | -4.4% |
| Gross Margin | 45.9% | 49.0% | -310 bps |
| Operating Income | $68.2 | $253.1 | -73.1% |
| Operating Margin | 2.0% | 7.5% | -550 bps |
| Net Income (Loss) Attributable to Common Shareholders | $(22.5) | $113.1 | -119.9% |
| Free Cash Flow | $43.3 | $136.0 | -68.2% |
| Total Debt (Outstanding) | $1.87 billion | $2.09 billion | -10.5% |
| Cash and Cash Equivalents | $298.8 | $183.4 | +62.9% |
Note: Non-GAAP Operating Income for 2025 was $433.1 million (12.6% margin), excluding restructuring, impairment, and acquisition-related costs.
Material Changes vs. Prior Period
- Revenue Growth: Organic revenue declined 3.7% on a constant currency basis, driven by weaker demand in industrial/semiconductor markets and fewer high-end NMR system sales. Growth was partially offset by acquisitions (ELITechGroup, NanoString) and strength in clinical/hospital markets.
- Profitability Decline: GAAP operating income dropped significantly due to a $96.5 million goodwill impairment charge (BSI NANO and BSI BioSpin segments), $77.4 million in restructuring costs, and increased cost of goods sold from U.S. tariffs and foreign exchange headwinds.
- Segment Performance:
- BSI CALID: Revenue increased 10.7% to $1,210.2 million, driven by ELITechGroup and Optics divisions.
- BSI BioSpin: Revenue decreased 3.0% to $878.8 million due to fewer GHz-class NMR sales.
- BSI NANO: Revenue decreased 1.3% to $1,084.3 million, impacted by weaker academic demand, partially offset by NanoString.
- BEST: Revenue decreased 4.3% to $270.9 million due to softness in the clinical MRI market.
- Capital Structure: The company issued $690 million of Series A Mandatory Convertible Preferred Stock in September 2025. Proceeds were used to repay $593.4 million in debt (2019 Term Loan, Revolving Credit Agreement, and 2024 Term Loan).
Guidance, Outlook, and Risks
- Cost Savings Initiative: In August 2025, management announced a plan to reduce annualized costs by $100–$120 million by the end of 2026 to improve operating margins.
- Tariff and Trade Policy: New U.S. tariffs imposed in 2025 have increased costs and reduced margins. A February 2026 Supreme Court ruling struck down certain tariffs, but the administration announced new tariffs on imports from all countries, creating ongoing uncertainty.
- Government Funding: Delays in U.S. academic funding (NIH, NSF, DOE) and Chinese government stimulus spending have negatively impacted bookings and revenue in academic and government sectors.
- Impairment Risks: The company recorded $96.5 million in goodwill impairment and $30.7 million in intangible asset impairment in 2025. Management warns that macroeconomic conditions could trigger additional charges.
- Backlog: Total remaining performance obligations increased to $2,569.4 million (from $2,090.4 million in 2024), primarily driven by higher BEST order bookings.
Key Facts for Investor Verification
- Impairment Drivers: Verify the specific assumptions used in the goodwill impairment tests for the Bruker Spatial Biology and Automation reporting units, particularly regarding revenue growth rates and discount rates.
- Tariff Impact Quantification: Assess the specific dollar impact of U.S. tariffs on Cost of Goods Sold and the potential for refunds following the Supreme Court ruling.
- Acquisition Integration: Monitor the integration progress and revenue contribution of major 2024 acquisitions (NanoString, ELITechGroup) and 2025 acquisitions (Recipe, AST Revolution).
- Preferred Stock Obligations: Review the terms of the Series A Mandatory Convertible Preferred Stock, including the 6.375% dividend rate and the mandatory conversion date (September 1, 2028).
- Government Funding Trends: Track updates on U.S. federal research funding levels and Chinese stimulus spending releases, as these are critical drivers for the academic and government customer base.